Journal article
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
JF Seymour, JM Bennett, AF List, GJ Mufti, SD Gore, P Fenaux, V Santini, J Hetzer, S Songer, BS Skikne, CL Beach
British Journal of Haematology | Published : 2014
DOI: 10.1111/bjh.12723
Abstract
The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA-001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of <30% cellularity were considered hypocellular with data evaluable from 299 patients (azacitidine n = 154, CCR n = 145); 13% (n = 39) hypocellular, 87% (n = 260) non-hypocellular. Patient characteristics were balanced between cellularity and treatment groups. Most patients (90-100%) had 2-3 cytopenias at baseline. Median (range) azacitidine treatment cycle leng..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The authors would like to thank Sheila Truten, BS, MC2, Wynnewood, PA, for editorial and writing assistance, which was supported by Celgene Corporation. The authors are fully responsible for all content and for editorial decisions made for this paper. Celgene Corporation funded the AZA-001 study.